London, ON, Canada
Feb 21, 2025
i-RNA Corporation, a pioneer in RNA-based therapeutics, is excited to join the Johnson & Johnson Innovation – JLABS @ Toronto as a resident company. This move aligns with i-RNA’s ongoing efforts to accelerate the development and commercialization of its innovative treatments for diabetic retinopathy (DR) and other ocular diseases.
This announcement comes shortly after JLABS @ Toronto’s own press release that welcomed i-RNA into its vibrant ecosystem. By joining JLABS, i-RNA gains access to state-of-the-art lab facilities, mentorship, and networking opportunities within the expansive Johnson & Johnson Innovation network, which will significantly bolster the company’s R&D capabilities and expedite its path to clinical trials.
Read JLABS’ official announcement here: JLABS Announcement
“We are thrilled to be part of the JLABS community, which will provide us with invaluable resources and support to advance our innovative RNA-based therapeutics,” said Ting Ling, CEO of i-RNA Corporation. “This partnership accelerates our mission to develop longer-lasting, more effective, and cost-efficient solutions for diabetic retinopathy and other vision-threatening conditions. By leveraging JLABS’ resources, we are one step closer to transforming patient care globally.”
i-RNA’s novel approach focuses on developing lncRNA-based therapeutics designed to be more effective, affordable, and durable than current treatments for DR. In preclinical studies, i-RNA has shown that its treatment can be delivered as an eyedrop, a potential breakthrough for improving patient compliance.
“We are excited to continue advancing our research and development efforts in this dynamic and innovative environment at JLABS,” continued Ting Ling. “With JLABS’ comprehensive support, we are well-positioned to bring our transformative therapies to market, benefiting millions of people suffering from vision loss.”
This announcement further reinforces i-RNA’s commitment to improving healthcare outcomes and lowering costs by addressing unmet medical needs in ocular diseases. The company is excited to build upon its progress with the help of JLABS @ Toronto and its robust network of life science innovators.